Clearnote Health
Danielle is an accomplished health policy strategist who has led teams across government affairs, market access, and reimbursement functions for over 25 years. Her extensive subject matter expertise guided innovative payment reforms across precision medicine diagnostics during her tenure at Sanofi Aventis, Genomic Health, Adaptive Biotechnologies, and Hologic. A principal voice in diagnostic health policy, Danielle has chaired the Coalition for 21st Century Medicine Reimbursement and Policy Workgroup, the California Healthcare Institute Diagnostic Workgroup, and participated in several CPT working groups for the American Medical Association. A member of leading federal and state diagnostic trade associations, Danielle earned her Master’s in Health Administration at Florida International University and a Bachelor of Science in Marketing from the University of Florida.
This person is not in any teams
Clearnote Health
ClearNote Health (formerly Bluestar Genomics) – Cancer detection company enabling people at risk for high-mortality cancers to live longer, healthier lives. They focus on developing non-invasive tests to detect cancer through a standard blood draw earlier than existing methods by harnessing the power of epigenomics. They apply their proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases. Headquartered in the U.S, the company’s CLIA and CAP-accredited laboratory is located in San Diego, Calif., with additional presence in the San Francisco Bay Area and internationally.